These constructs are often designed to exploit the increased expression of GLUTs (particularly GLUT1) in many tumors, thereby promoting preferential uptake into cancer cells while reducing systemic toxicity and increasing water solubility to improve pharmacokinetic properties [51]. This evidence concerns the gene SLC2A1 and cancer.